Parkinson's Disease Therapeutics Pipeline Program
The Michael J. Fox Foundation for Parkinson's Research
Don't lose track of this one
We'll email you once about this listing. No list, no cadence.
Free. Verify your email, then we send one reminder only.
- Posted
- Jun 10, 2026
- Closes
- Rolling intake; check eligibility
Similar opportunities open now
- Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN) Powering the Next Generation of ResearchSame funderOpenThe Michael J. Fox Foundation for Parkinson's ResearchNo deadline listedUp to $250K
- CFF: Path to a Cure Pioneer AwardOpenCystic Fibrosis FoundationCloses Dec 5, 2026 (in 32 days)
- Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)OpenNational Institutes of HealthCloses Dec 2027
- Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)OpenNational Institutes of HealthCloses Nov 2027Up to $1.5M
- Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)OpenNational Institutes of HealthCloses Aug 2027
Amount
Amount not listed here. Check the official program.
Who can apply
Who Can Apply Open to industry, academic/industry partnerships, and—in certain cases—academic-led projects; access the downloadable RFA overview below for full eligibility details…
About this opportunity
Our flagship funding initiative accelerates Parkinson’s disease therapy development by prioritizing opportunities where our funding supports generation of meaningful evidence informing critical development milestones. We are charting the path to a future free from Parkinson’s. Your support will get us there. Our flagship funding initiative accelerates Parkinson’s disease therapy development by prioritizing opportunities where our funding supports generation of meaningful evidence informing critical development milestones. As the primary focus of TPP is to advance new therapeutic interventions, MJFF will NOT consider proposal submissions to this program that focus on the following areas: